Trebia (TREB) Shareholders Approve System1 Deal
by Marlena Haddad on 2022-01-20 at 4:29pm

Trebia Acquisition Corp. (NYSE:TREB) announced that its shareholders approved its combination with marketing platform System1 and Protected.net in a special meeting held earlier today.

Although the press release did not disclose redemption amounts, TREB traded below $10 throughout its redemption deadline January 18, and opened today at $8.23.  The SPAC is currently down by 1.34% at $8.09 following the headlines.

Earlier this month, Trebia added $50 million to it’s existing backstop, bringing the transaction to a total of $650 million of fully committed financing including a $400 million syndicated term loan from BofA Securities and $250 million from Cannae’s (NYSE:CNNE) updated backstop. This committed financing, in addition to the management’s agreement to reinvest additional equity, will cover up to 100% of potential redemptions by TREB’s shareholders.

Trebia originally brought about $518 million into the transaction from its current trust and Cannae initially committed to a $200 million equity backstop with $218 million more in debt commitments by BofA Securities (NYSE:BAC) to cover redemptions.

The transaction is expected to close shortly and the combined company’s common stock is expected to trade on the New York Stock Exchange under the ticker symbol “SST”.

Trebia and System1 initially announced their $1.4 billion deal on June 29. Los Angeles-based System1 connects advertisers with internet users through a portfolio of websites and AI-powered marketing tools.

Approximately 93.57% of the votes cast at today’s special meeting were in favor of the business combination with 68.63% of Trebia’s outstanding shares voting.


ADVISORS

  • Evercore is acting as exclusive financial advisor to System1.
  • Latham & Watkins LLP and Willkie Farr & Gallagher LLP are acting as legal advisors to System1.
  • Trethowans and Greenberg Glusker are acting as legal advisors to Protected.net.
  • BofA Securities is acting as lead financial and capital markets advisor to Trebia
  • Credit Suisse and Moelis & Company are also acting as capital markets advisors to Trebia.
  • Weil, Gotshal & Manges LLP is acting as legal advisor to Trebia
Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved